Telix Pharmaceuticals' (ASX:TLX) unaudited revenue for the first quarter reached AU$186 million, an increase of 62% from AU$115 million in the year-ago period, according to a Tuesday filing with the Australian bourse.

This comprised AU$151 million from global sales of Illuccix and AU$33 million from RLS Radiopharmacies, which was acquired in January.

The biopharmaceutical company reaffirmed its FY2025 revenue guidance of AU$770 million to AU$800 million. It noted that this will be updated "at the appropriate time" to take into account reimbursement for Gozellix in the US and Illuccix in ex-US markets, per the filing.